Sign In
Buy PSTV
$5.42
-0.0500 (-0.91%)
At Close: Jun 03, 2026
Plus Therapeutics (PSTV) Reports Q4 Loss, Tops Revenue Estimates
06:36pm, Tuesday, 05'th Mar 2024
Plus Therapeutics (PSTV) came out with a quarterly loss of $0.70 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to loss of $2.40 per share a year ago.
Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
04:05pm, Tuesday, 05'th Mar 2024
Began enrollment of the 5 th of an anticipated 7 planned dosing cohorts for the ReSPECT-LM Phase 1 dose escalation trial with rhenium ( 186 Re) obisbemeda for leptomeningeal metastases (LM)
Plus Updates Financial and Cash Guidance for 2024
07:00am, Monday, 18'th Dec 2023
Plus Receives $3.3M in grant revenue in Q4 2023 Forecasts additional $6.9M of grant revenue for 2024 Enters into debt restructuring deal with Pershing Capital to reduce 2024 cash burn by $3.7M AUSTIN,
AUSTIN, Texas, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanc
Penny Stocks To Buy Now? 4 To Watch Before Next Week
10:05am, Friday, 03'rd Nov 2023
Penny stocks, also known as micro-cap equities or stocks under $5 per share, offer investors affordable opportunities. This is to buy shares in emerging small companies early before potential growth a
AUSTIN, Texas, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advan
Plus Therapeutics, Inc. (PSTV) Q3 2023 Earnings Call Transcript
07:46pm, Tuesday, 31'st Oct 2023
Plus Therapeutics, Inc. (NASDAQ:PSTV ) Q3 2023 Earnings Conference Call October 31, 2023 5:00 PM ET Corporate Participants Marc Hedrick - President and Chief Executive Officer Andrew Sims - Vice Presi
Plus Therapeutics Announces Share Repurchase Program
04:10pm, Tuesday, 31'st Oct 2023
AUSTIN, Texas, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advance
Plus Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
04:05pm, Tuesday, 31'st Oct 2023
New survival data from 15 patients in the Phase 2 ReSPECT-GBM trial of rhenium ( 186 Re) obisbemeda in recurrent glioblastoma (rGBM) will be presented at SNO Annual Meeting on November 17 th ; Company
Plus Therapeutics to Present at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinar
09:21am, Wednesday, 25'th Oct 2023
Update on the ReSPECT-GBM Trial, including Phase 2, with Rhenium-186 Obisbemeda in Recurrent Glioblastoma will be Presented at SNO Annual Meeting Update on the ReSPECT-GBM Trial, including Phase 2, wi
Plus Therapeutics to Announce Third Quarter 2023 Financial Results and Host Conference Call on October 31, 2023
04:05pm, Monday, 23'rd Oct 2023
AUSTIN, Texas, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advan
AUSTIN, Texas, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with adva
Plus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
07:00am, Wednesday, 30'th Aug 2023
AUSTIN, Texas, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technolo
Plus Therapeutics, Inc. (PSTV) Q2 2023 Earnings Call Transcript
09:52pm, Monday, 14'th Aug 2023
Plus Therapeutics, Inc. (NASDAQ:PSTV ) Q2 2023 Earnings Conference Call August 14, 2023 5:00 PM ET Corporate Participants Marc Hedrick - President and Chief Executive Officer Andrew Sims - Chief Finan
Plus Therapeutics to Announce Second Quarter 2023 Financial Results and Host Conference Call on August 14, 2023
04:05pm, Tuesday, 08'th Aug 2023
AUSTIN, Texas, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics
